Every compound we cover — what it is and where the evidence stands. Approved drugs are named as approved, animal-only evidence is named as animal-only, and popular-but-unstudied compounds are called exactly that.
evidence key — clinical = published human data · community = gray-market adoption · rated separately, on purpose
A gray-market derivative of Semax sold in the nootropic scene. It has essentially no published research of its own — the case for it is anecdote plus extrapolation from the parent compound.
A copper-binding tripeptide marketed mainly for hair growth. The published evidence amounts to a handful of cell and small cosmetic studies — far thinner than the literature behind its cousin GHK-Cu.
An AMPK-activating nucleoside analog rather than a true peptide — covered because research vendors sell it alongside them. Known from animal endurance studies, and it appears on sport anti-doping prohibited lists.
A fragment of human growth hormone studied for fat metabolism. It went through early human trials without reaching approval, and the evidence for meaningful fat loss remains thin.
An erythropoietin-derived peptide, also called cibinetide, studied for nerve repair. Unusually for this index it has real early-stage human trial data in small-fiber neuropathy — it remains investigational and unapproved.
A long-acting amylin analog in development for weight management, studied mostly in combination with semaglutide. Investigational — in late-stage trials, approved nowhere.
A GHRH analog engineered for a longer half-life, sold with or without the DAC modification. Early human studies showed it raises growth hormone and IGF-1, but development stopped and it was never approved.
A myostatin-binding protein sold with muscle-growth claims well beyond what the evidence supports. The data is animal work plus gene-therapy research — the human studies involve gene delivery, not the injected peptide the market sells.
A cell-penetrating peptide designed to push senescent cells into self-destruction. A genuinely interesting senolytic idea — with preclinical-only data. The striking results are in mice, not people.
Copper tripeptide with genuine published data on skin remodeling and wound healing — one of the better-evidenced cosmetic peptides. Most of that work concerns topical use rather than injection.
An early growth-hormone-releasing peptide acting on the ghrelin receptor. Studied in small human GH-response experiments; it was never developed to approval.
A first-generation GH secretagogue known for a strong hunger effect through ghrelin signaling. Human data is limited to small mechanistic studies, and no approval was ever pursued to completion.
The body's own tripeptide antioxidant, widely sold for injection and IV use. It is a true tripeptide rather than a signaling hormone — we cover it because the market sells it alongside peptides, and evidence for injected use in healthy people is limited.
Synthetic GnRH, identical to the native hormone, which has held FDA approval as a diagnostic agent. In the research market it circulates for supporting the reproductive hormone axis during hormone protocols.
A potent GH secretagogue studied in small human experiments, with published work noting the growth hormone response fades on continued use. Never approved for any indication.
A mitochondrial-derived peptide studied in aging and neuroprotection models. The evidence is preclinical — animal and cell work, with no meaningful human trials.
A tripeptide fragment of alpha-MSH studied for anti-inflammatory activity, mostly in gut-inflammation models. The evidence is preclinical — animal and cell studies, not human trials.
A fragment of the native hormone that sits at the top of the reproductive hormone axis. It has been used in real human physiology experiments, but it is a research probe, not a developed drug.
A daily GLP-1 receptor agonist, FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management. An older member of the class with a long clinical record.
The human cathelicidin antimicrobial peptide, part of innate immunity. Heavily studied in the laboratory — but injecting it in healthy people has no clinical evidence base at all.
The same molecule as afamelanotide, approved as Scenesse for a rare light-sensitivity disorder — which makes it an approved drug in that form. Gray-market use for tanning sits well outside that approval.
A synthetic melanocortin agonist sold for tanning. It has never been approved for any use, and it has drawn safety warnings from medicines regulators in several countries.
A mitochondrial-derived peptide studied in metabolism and exercise models. Almost all of the evidence is animal or cell work — human data is minimal and very early.
A pegylated form of mechano growth factor, an IGF-1 splice-variant fragment sold for muscle repair. The evidence is animal and in-vitro work — human trial data does not exist.
A short bioregulator peptide from the Russian research tradition, claimed to support brain function. The literature is small, old, and largely confined to Russian journals — Western evidence is thin.
Bremelanotide — a melanocortin agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. A rare case of a fully approved drug circulating in the research market.
A tuftsin-analog anxiolytic peptide from the same Russian research tradition as Semax. Clinical use and trial data exist in Russia; Western controlled evidence is minimal.
A GLP-1 receptor agonist, FDA-approved as Ozempic for type 2 diabetes and Wegovy for weight management. One of the most thoroughly trialed compounds on this index.
A synthetic ACTH-fragment analog developed in Russia, where it has clinical use for stroke and cognitive complaints. Western controlled trials are essentially absent.
A GHRH fragment that was once an FDA-approved drug, marketed as Geref before being discontinued. That history gives it more human data than most GH peptides sold today.
Also known as elamipretide — a mitochondria-targeted peptide that has been through genuine clinical trials in mitochondrial disease and heart conditions. It remains investigational and unapproved.
A dual GLP-1 and glucagon receptor agonist in clinical development for obesity and liver disease. Investigational — phase 3 stage, not approved anywhere.
A synthetic fragment of thymosin beta-4 sold for injury recovery. The supporting evidence is animal and cell work — controlled human data is lacking.
A GHRH analog, FDA-approved as Egrifta for HIV-associated lipodystrophy. That approval means it carries real human efficacy data most GH peptides lack.
A thymic peptide approved in a number of countries as Zadaxin, mainly for hepatitis and as an immune adjuvant, though it holds no FDA approval in the US. One of the better-evidenced immune peptides.
A zinc-dependent thymic hormone studied in immune-regulation models since the 1970s. The evidence is largely animal and in-vitro — human data is scarce.
A dual GLP-1 and GIP receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management. The benchmark the rest of the class is measured against.
Every blurb on this page follows one rule — the evidence is described at the level it actually exists. Approved drugs are named as approved, animal-only data is named as animal-only, and thin literatures are called thin. The full grading criteria live in our editorial policy, and the companion skill is learning to read a certificate of analysis before you believe a label.